Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
7
3
2024
Statut:
aheadofprint
Résumé
Target therapy for metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RAS genes (KRAS/NRAS) are mutated in 40-60% of metastatic colorectal cancer and BRAF in 5-10%. The presence of a double mutation in RAS and BRAF is rare. Therefore, RAS and BRAF mutations were considered exclusive. Herein, we describe a novel concomitant NRAS/BRAF mutation identified in a series of 865 colorectal cancer patients.
Identifiants
pubmed: 38451831
doi: 10.1097/CAD.0000000000001586
pii: 00001813-990000000-00253
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract 2022; 28:850–869.
Afrasanie VA, Gafton B, Marinca MV, Alexa-Stratulat T, Miron L, Rusu C, et al. The coexistence of RAS and BRAF mutations in metastatic colorectal cancer: a case report and systematic literature review. J Gastrointestin Liver Dis 2020; 29:251–256.
Uchida S, Kojima T, Sugino T. Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study. Pathol Oncol Res 2022; 28:1610206.
Liu T, Jiang S, Teng X, Zhong L, Liu M, Jin Y, et al. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Immunopharmacol Immunotoxicol 2023; 45:1–9.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753–762.
Martinelli E, Troiani T, Cardone C, Ciardiello D, Zanaletti N, Borrelli C, et al. Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon. Ann Oncol 2019; 30:v251.
Mauri G, et al. The evolutionary landscape of treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021; 13:137.
Bozyk A, Krawczyk P, Reszka K, Krukowska K, Kolak A, Mańdziuk S, et al. Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer. Arch Med Sci 2022; 18:1221–1230.
Cao MN, Chen K-T, Li Q-F, Wang Li, Jin G-W, Na R-T, et al. Development of BRAF V600E Mutation in NRAS Q61L Mutated Rectal Cancer. Ann Clin Lab Sci 2021; 51:262–266.
Deshwar A, Margonis GA, Andreatos N, Barbon C, Wang J, Buettner S, et al. Double KRAS and BRAF mutations in surgically treated colorectal cancer liver metastases: an international, multi-institutional case series. Anticancer Res 2018; 38:2891–2895.
Zheng G, Tseng L-H, Chen G, Haley L, Illei P, Gocke CD, et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer 2015; 15:779.
Zelli V, Parisi A, Patruno L, Cannita K, Ficorella C, Luzi C, et al. Concurrent RAS and RAS/BRAF V600E variants in colorectal cancer: more frequent than expected? a case report. Front Oncol 2022; 12:863639.
Isnaldi E, Garuti A, Cirmena G, Scabini S, Rimini E, Ferrando L, et al. Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. J Transl Med 2019; 17:137.
Mikolajcik P, Lasabova Z, Loderer D, Grendar M, Kalman M, Kasubova I, et al. Detection of therapeutically relevant and concomitant rare somatic variants in colorectal cancer. Neoplasma 2021; 68:1331–1340.
Midthun L, Shaheen S, Deisch J, Senthil M, Tsai J, Hsueh C-T. Concomitant KRAS and BRAF mutations in colorectal cancer. J Gastrointest Oncol 2019; 10:577–581.
Vittal A, Sharma D, Samanta I, Kasi A. Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma. BMJ Case Rep 2019; 12:e221816.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 2017; 548:234–238.
Javed S, Benoist S, Devos P, Truant S, Guimbaud R, Lièvre A, et al. Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. World J Surg Oncol 2022; 20:131.